Furthermore, given its selective expression in malignant tumor components, RALYL-based therapeutic approaches—such as targeted therapy, tumor vaccines, or CAR-T cell therapy—could offer potential clinical applications (32). This evidence concerns the gene RALYL and neoplasm.